Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HS for at least 1 year prior to screening~* HS lesions must be present in at least 2 distinct anatomic areas~* A total AN count (sum of abscesses and inflammatory nodules) \> 6 across all anatomical sites at both the screening and baseline visits~* Willing to use contraception for the duration of the study~Exclusion Criteria:~* Presence of other skin conditions which may interfere with study assessments~* Presence of active, chronic or latent bacterial, viral, fungal mycobacterial infection (including latent TB) or history of infection within 4 weeks of screening~* Body Mass Index (BMI) \>48kg/m2~* Breastfeeding or pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RIST4721 400 mg (Type: EXPERIMENTAL): RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 4 placebo tablets once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).